Charles River Laboratories International Inc
NYSE:CRL

Watchlist Manager
Charles River Laboratories International Inc Logo
Charles River Laboratories International Inc
NYSE:CRL
Watchlist
Price: 186.29 USD 0.49% Market Closed
Market Cap: 9.5B USD
Have any thoughts about
Charles River Laboratories International Inc?
Write Note

Charles River Laboratories International Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Charles River Laboratories International Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Charles River Laboratories International Inc
NYSE:CRL
Income from Continuing Operations
$428m
CAGR 3-Years
2%
CAGR 5-Years
13%
CAGR 10-Years
13%
Thermo Fisher Scientific Inc
NYSE:TMO
Income from Continuing Operations
$6.2B
CAGR 3-Years
-10%
CAGR 5-Years
11%
CAGR 10-Years
14%
Danaher Corp
NYSE:DHR
Income from Continuing Operations
$3.6B
CAGR 3-Years
-15%
CAGR 5-Years
11%
CAGR 10-Years
3%
Mettler-Toledo International Inc
NYSE:MTD
Income from Continuing Operations
$795.6m
CAGR 3-Years
2%
CAGR 5-Years
8%
CAGR 10-Years
9%
Agilent Technologies Inc
NYSE:A
Income from Continuing Operations
$1.3B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
19%
IQVIA Holdings Inc
NYSE:IQV
Income from Continuing Operations
$1.4B
CAGR 3-Years
22%
CAGR 5-Years
39%
CAGR 10-Years
16%
No Stocks Found

Charles River Laboratories International Inc
Glance View

Market Cap
9.5B USD
Industry
Life Sciences Tools & Services
Economic Moat
None

Nestled within the intricate maze of the global life sciences sector, Charles River Laboratories International Inc. stands as a pivotal player. With a legacy dating back to 1947, the company has carved out a niche in providing essential research models and preclinical services that underpin crucial drug development processes. Its journey began by breeding laboratory animals, an unassuming yet vital task that feeds the robust pipeline of scientific inquiry and pharmaceutical innovation. This foundational service, involving the provision of research models such as rats and mice, forms the bedrock upon which the company built its expansive portfolio. It primes the pumps of early-stage research for pharmaceutical and biotechnology firms, offering a reliable source of high-quality, disease-specific models that are indispensable for preclinical trials. Today, Charles River Laboratories has evolved into a comprehensive partner for the biomedical and pharmaceutical industries. It derives its revenue by encompassing a broad portfolio of offerings beyond animal models, venturing into the vast domain of comprehensive drug discovery and safety testing for new pharmaceuticals. This makes the company instrumental in speeding up the development pipeline—from concept to the cusp of clinical trials. By providing everything from lab services, safety assessments, and manufacturing support, Charles River facilitates the journey of a drug from an embryonic idea to a tangible, market-ready solution, all while ensuring compliance with strict regulatory standards. This integration across verticals not only enriches its value proposition but ensures a steady stream of revenue across various stages of the drug development lifecycle.

CRL Intrinsic Value
232.86 USD
Undervaluation 20%
Intrinsic Value
Price

See Also

What is Charles River Laboratories International Inc's Income from Continuing Operations?
Income from Continuing Operations
428m USD

Based on the financial report for Sep 28, 2024, Charles River Laboratories International Inc's Income from Continuing Operations amounts to 428m USD.

What is Charles River Laboratories International Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
13%

Over the last year, the Income from Continuing Operations growth was -11%. The average annual Income from Continuing Operations growth rates for Charles River Laboratories International Inc have been 2% over the past three years , 13% over the past five years , and 13% over the past ten years .

Back to Top